Increased Neutralization Potency and Breadth Elicited by a SARS-CoV-2 mRNA Vaccine Forming Virus-Like Particles

Researchers applied a mRNA forming vaccine virus-like particles (VLPs) platform to SARS-CoV-2 to evaluate potential improvements. To facilitate the assembly of VLPs, they replaced the native cytoplasmic tail of the SARS-CoV-2 Spike protein with that of simian immunodeficiency virus.